Esophageal and Gastroesophageal Junction Carcinoma

Esophageal and Gastroesophageal Junction Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

1,309 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 460
Recruiting: 254
Ph III recruiting: 40
Growth YoY: +36.1%
Industry share: 22%
Top sponsor: National Cancer Institute (NCI)
Termination share: 29.1%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (120)

clinicaltrialsPublishedShowing 51–99 of 99 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07284186	First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors	recruiting	Phase 1	155	Plexium, Inc.INDUSTRY	1	Jun 12, 2026	clinicaltrials
NCT07218003	A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4	enrolling by invitation	Phase 1	149	Rondo TherapeuticsINDUSTRY	1	Jun 11, 2026	clinicaltrials